Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
1,091
Views
1
CrossRef citations to date
0
Altmetric
Mental Health

Place of care and costs associated with acute episodes and remission in bipolar I disorder

Roger S. McIntyrea Department of Psychiatry, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4733-2523
ORCID Icon,
Sara Higab AbbVie, Irvine, CA, USA
,
Quan V. Doanc Genesis Research, Hoboken, NJ, USA
,
Diana Amaric Genesis Research, Hoboken, NJ, USA
,
David Oliveric Genesis Research, Hoboken, NJ, USA
,
Patrick Gillardb AbbVie, Irvine, CA, USA
&
Amanda Harringtonb AbbVie, Irvine, CA, USA
 show all
Pages 1110-1117 | Received 08 Apr 2022, Accepted 30 Aug 2022, Published online: 22 Sep 2022

References

  • Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the national epidemiologic survey on alcohol and related conditions – III. J Psychiatr Res. 2017;84:310–317.
  • Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537.
  • McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–1856.
  • Bonnin CDM, Reinares M, Martinez-Aran A, et al. Improving functioning, quality of life, and well-being in patients with bipolar disorder. Int J Neuropsychopharmacol. 2019;22(8):467–477.
  • Khafif TC, Belizario GO, Silva M, et al. Quality of life and clinical outcomes in bipolar disorder: an 8-year longitudinal study. J Affect Disord. 2021;278:239–243.
  • Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83.
  • Bessonova L, Ogden K, Doane MJ, et al. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481–497.
  • Cloutier M, Greene M, Guerin A, et al. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51.
  • Culpepper L, Higa S, Martin A, et al. Reduced health-related quality of life and increased costs associated with bipolar I disorder. Poster presented at the Psych Congress. San Antonio, TX; 2021.
  • Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398–405.
  • Hirschfeld RM, Calabrese JR, Frye MA, et al. Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull. 2007;40(3):7–14.
  • Rolin D, Whelan J, Montano CB. Is it depression or is it bipolar depression? J Am Assoc Nurse Pract. 2020;32(10):703–713.
  • Allergan. Vraylar® (cariprazine) prescribing information. Madison (NJ); 2019.
  • Deeks ED, Keating GM. Spotlight on olanzapine/fluoxetine in acute bipolar depression. CNS Drugs. 2008;22(9):793–795.
  • Intra-Cellular Therapies Announces US FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults. Intra-Cellular Therapies. [cited 2021 Dec 20]. Available from: https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar.
  • Alembic Pharmaceuticals. Lurasidone hydrochloride prescribing information. Bridgewater (NJ); 2019.
  • ACI Healthcare. Quetiapine extended release prescribing information. Cora Springs (FL); 2021.
  • Novartis Pharmaceuticals Corporation. Clozaril® prescribing information. East Hanover (NJ); 2014.
  • Florida Medicaid Drug Therapy Management Program for Behavioral Health, University of South Florida College of Behavioral & Community Sciences. Psychotherapeutic Medication Guidelines for Adults 2019-2020. Agency for Health Care Administration State of Florida; 2019. Available from: https://floridabhcenter.org/.
  • Wilkowska A, Cubała WJ. Clozapine as transformative treatment in bipolar patients. Neuropsychiatr Dis Treat. 2019;15:2901–2905.
  • Costa MH, Kunz M, Nierenberg AA, et al. Clozapine and the course of bipolar disorder in the systematic treatment enhancement program for bipolar disorder (STEP-BD): La clozapine et l’évolution du trouble bipolaire dans le programme d’amélioration systématique du traitement du trouble bipolaire (STEP-BD). Can J Psychiatry. 2020;65(4):245–252.
  • Shah N, Grover S, Rao GP. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry. 2017;59(Suppl 1):S51–S66.
  • Al Jurdi RK, Schulberg HC, Greenberg RL, et al. Characteristics associated with inpatient versus outpatient status in older adults with bipolar disorder. J Geriatr Psychiatry Neurol. 2012;25(1):62–68.
  • Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics. 2001;19(5 Pt 1):483–495.
  • Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Suppl 1):S3–S11.
  • Bergeson JG, Kalsekar I, Jing Y, et al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits. 2012;5(6):379–386.
  • Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(03):453–460.
  • Chakrabarti S. Treatment-adherence in bipolar disorder: a patient-centred approach. World J Psychiatry. 2016;6(4):399–409.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.